Strategic Focus ImmunoDX operates in Biotechnology Research with a targeted portfolio of human T-cell research, diagnostics, AIDS, HCV, HBV, TB, cancer, and arthritis therapeutics. This breadth suggests cross-sell opportunities to labs and institutions focused on immunology, infectious diseases, and oncology, particularly those requiring recombinant proteins and monoclonal antibodies.

Quality & Product Line The company emphasizes high-purity, specificity, and biological activity in its proprietary reagents, including recombinant proteins and derivatized antibodies. Sales opportunities exist in research and clinical screening settings that demand reliable, validated reagents for assay development, diagnostics, and therapeutic research.

Scale & Partners With a small team (2-10 employees) but a product suite aligned to major diagnostics and therapeutic areas, ImmunoDX may benefit from distribution partnerships, contract manufacturing, or white-labeling arrangements to expand market reach without significant headcount growth.

Digital Presence The tech stack includes modern web and analytics tools, indicating potential for enhanced e-commerce, lead capture, and customer self-service. Investment in digital marketing and technical content could improve outbound reach to biotech labs, academic researchers, and biotech startups.

Revenue Signals Reported revenue in the $1M–$10M range signals a growing, mid-market footprint. Target accounts could include mid-sized pharmaceutical and CROs, teaching hospitals, and university biotech departments seeking specialized reagents and custom antibody services to complement larger suppliers.